Antitumor activity of combined endostatin and thymidine kinase gene therapy in C6 glioma models

Cancer Medicine

Volumn 5, Issue 9, 2016, Pages 2477-2486

  Chen, Yan ^a   Huang, Honglan ^b   Yao, Chunshan ^a   Su, Fengbo ^a   Guan, Wenming ^a   Yan, Shijun ^a   Ni, Zhaohui ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

C6 glioma; endostatin (ES); Ganciclovir; thymidine kinase (TK); tumor inhibition

Indexed keywords

ENDOSTATIN; THYMIDINE KINASE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C6 CELL LINE; CANCER CELL; CAPILLARY DENSITY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ECV304 CELL LINE; ENDOPLASMIC RETICULUM; GENE THERAPY; GLIOMA; GLIOMA CELL LINE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

EID: 84991086733     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.798     Document Type: Article

References (31)

1. Omuro, A., and L. M. DeAngelis. 2013. Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850.
2. Chowdhary, M. M., C. I. Ene, and D. L. Silbergeld. 2015. Treatment of Gliomas: how did we get here? Surg. Neurol. Int. 6:S85–S88.
3. Zahonero, C., and P. Sanchez-Gomez. 2014. EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cell. Mol. Life Sci. 71:3465–3488.
4. Okura, H., C. A. Smith, and J. T. Rutka. 2014. Gene therapy for malignant glioma. Mol. Cell. Ther. 2:21.
5. Bansal, K., and H. H. Engelhard. 2000. Gene therapy for brain tumors. Curr. Oncol. Rep. 2:463–472.
6. Tobias, A., A. Ahmed, K. S. Moon, and M. S. Lesniak. 2013. The art of gene therapy for glioma: a review of the challenging road to the bedside. J. Neurol. Neurosurg. Psychiatry 84:213–222.
7. Gatson, N. N., E. A. Chiocca, and B. Kaur. 2012. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci. Lett. 527:62–70.
8. Brat, D. J., R. G. Verhaak, K. D. Aldape, W. K. Yung, S. R. Salama, L. A. Cooper, et al. 2015. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372:2481–2498.
9. Moolten, F. L. 1986. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46:5276–5281.
10. Fischer, U., S. Steffens, S. Frank, N. G. Rainov, K. Schulze-Osthoff, and C. M. Kramm. 2005. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene 24:1231–1243.
11. Yang, L., Z. Lin, J. Lin, S. Weng, Q. Huang, P. Zhang, et al. 2011. Antitumor effect of endostatin overexpressed in C6 glioma cells is associated with the down-regulation of VEGF. Int. J. Oncol. 38:465–471.
12. Zhang, G., G. Jin, X. Nie, R. Mi, G. Zhu, W. Jia, et al. 2014. Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts. PLoS ONE 9:e95872.
13. Barth, R. F., and B. Kaur. 2009. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J. Neurooncol. 94:299–312.
14. Zhen, H. N., X. Zhang, P. Z. Hu, T. T. Yang, Z. Fei, J. N. Zhang, et al. 2005. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775–2783.
15. Candolfi, M., K. M. Kroeger, A. K. Muhammad, K. Yagiz, C. Farrokhi, R. N. Pechnick, et al. 2009. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr. Gene Ther. 9:409–421.
16. Renaud-Gabardos, E., F. Hantelys, F. Morfoisse, X. Chaufour, B. Garmy-Susini, and A. C. Prats. 2015. Internal ribosome entry site-based vectors for combined gene therapy. World J. Exp. Med. 5:11–20.
17. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674.
18. Casey, S. C., M. Vaccari, F. Al-Mulla, R. Al-Temaimi, A. Amedei, M. H. Barcellos-Hoff, et al. 2015. The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis 36(Suppl 1):S160–S183.
19. Jeon, H. M., S. H. Kim, X. Jin, J. B. Park, K. Joshi, I. Nakano, et al. 2014. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res. 74:4482–4492.
20. Charles, N. A., E. C. Holland, R. Gilbertson, R. Glass, and H. Kettenmann. 2012. The brain tumor microenvironment. Glia 60:502–514.
21. Wang, Z., C. Dabrosin, X. Yin, M. M. Fuster, A. Arreola, and W. K. Rathmell, et al. 2015. Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol. 35:S224–S243.
22. O'Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285.
23. Persano, L., M. Crescenzi, and S. Indraccolo. 2007. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol. Aspects Med. 28:87–114.
24. Ferreras, M., U. Felbor, T. Lenhard, B. R. Olsen, and J. Delaisse. 2000. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486:247–251.
25. Dixelius, J., H. Larsson, T. Sasaki, K. Holmqvist, L. Lu, A. Engstrom, et al. 2000. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95:3403–3411.
26. Lu, K. V., J. P. Chang, C. A. Parachoniak, M. M. Pandika, M. K. Aghi, D. Meyronet, et al. 2012. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21–35.
27. Greco, R., G. Oliveira, M. T. Stanghellini, L. Vago, A. Bondanza, J. Peccatori, et al. 2015. Improving the safety of cell therapy with the TK-suicide gene. Front. Pharmacol. 6:95.
28. Wahlfors, T., A. Karppinen, J. Janne, L. Alhonen, and J. Wahlfors. 2006. Polyamine depletion and cell cycle manipulation in combination with HSV thymidine kinase/ganciclovir cancer gene therapy. Int. J. Oncol. 28:1515–1522.
29. Pan, J. G., X. Zhou, G. W. Zeng, and R. F. Han. 2012. Potent antitumour activity of the combination of HSV-TK and endostatin armed oncolytic adeno-associated virus for bladder cancer in vitro and in vivo. J. Surg. Oncol. 105:249–257.
30. Pan, J. G., R. Q. Luo, X. Zhou, R. F. Han, and G. W. Zeng. 2013. Potent antitumor activity of the combination of HSV-TK and endostatin by adeno-associated virus vector for bladder cancer in vivo. Clin. Lab. 59:1147–1158.
31. Pan, J. G., R. Q. Luo, X. Zhou, R. F. Han, and G. W. Zeng. 2013. Suppression of bladder cancer growth by adeno-associated virus vector-mediated combination of HSV-TK and endostatin in vitro. Clin. Lab. 59:1077–1089.